Research Papers:

Hormone receptor expression profiles differ between primary and recurrent high-grade serous ovarian cancers

Zheng Feng, Hao Wen, Xingzhu Ju, Rui Bi, Xiaojun Chen, Wentao Yang and Xiaohua Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:32848-32855. https://doi.org/10.18632/oncotarget.15858

Metrics: PDF 1399 views  |   HTML 2646 views  |   ?  


Zheng Feng1,2,*, Hao Wen1,2,*, Xingzhu Ju1,2, Rui Bi2,3, Xiaojun Chen1,2, Wentao Yang2,3 and Xiaohua Wu1,2

1Department of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

3Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

*These authors have contributed equally to this work

Correspondence to:

Xiaohua Wu, email: [email protected], [email protected]

Keywords: high-grade serous ovarian cancer, hormone receptors, estrogen receptor, progesterone receptor, androgen receptor

Received: July 26, 2016    Accepted: December 07, 2016    Published: March 02, 2017


Hormone receptor status assessment is necessary for selecting cancer patients who might potentially benefit from endocrine therapy. To determine whether hormone receptor status changes during tumor progression, we retrospectively examined 107 high-grade serous ovarian cancer (HGSC) patients with paired primary and recurrent tumor specimens. Hormone receptor expression discordance rates between primary and recurrent tumors were as follows: estrogen receptor (ER) 34.9%, progesterone receptor (PR) 12.4%, androgen receptor (AR) 41.7%, follicle stimulating hormone receptor 46.6%, luteinizing hormone receptor 50.5%, and gonadotropin releasing hormone receptor 20.0%. Hormone receptor discordance was not associated with patient survival. The proportion of the PR-ER+AR- subgroup, which exhibited the worst prognosis, was higher in recurrent than primary tumor specimens. Our study demonstrated that paired primary and recurrent HGSC specimens exhibit differing hormone receptor profiles. Thus, to most effectively identify patient-specific therapies, biomarker status re-assessment is required for recurrent patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15858